Clinical Microbiology Newsletter最新文献_第5页

Microbe snapshots: Dengue virus 微生物快照：登革热病毒

Clinical Microbiology Newsletter Pub Date : 2025-03-01 Epub Date: 2024-11-26 DOI: 10.1016/j.clinmicnews.2024.11.002

Samuel M. Goodfellow , Esther Vaugon

引用次数: 0

Bilateral otitis media as an initial manifestation of disseminated tuberculosis disease in a patient with late HIV infection diagnosis 双侧中耳炎是一名晚期艾滋病毒感染患者播散性结核病的初期表现

Clinical Microbiology Newsletter Pub Date : 2025-03-01 Epub Date: 2024-11-07 DOI: 10.1016/j.clinmicnews.2024.10.004

Victoria Lobo-Antuña , Marta Lobo-Antuña , Juan Martínez-Andrés , Cristina Rodríguez-Prado , María Remedios Guna-Serrano , Atilio Navarro-Gonzales , Magdalena García-Rodríguez , Carmen Ricart-Olmos

{"title":"Bilateral otitis media as an initial manifestation of disseminated tuberculosis disease in a patient with late HIV infection diagnosis","authors":"Victoria Lobo-Antuña , Marta Lobo-Antuña , Juan Martínez-Andrés , Cristina Rodríguez-Prado , María Remedios Guna-Serrano , Atilio Navarro-Gonzales , Magdalena García-Rodríguez , Carmen Ricart-Olmos","doi":"10.1016/j.clinmicnews.2024.10.004","DOIUrl":"10.1016/j.clinmicnews.2024.10.004","url":null,"abstract":"<div><div>Tuberculous otitis media is a rare form of extrapulmonary tuberculosis, often resulting in delayed diagnosis due to its nonspecific symptoms and low clinical suspicion. We present the case of a 29-year-old woman with initial symptoms of sudden speech impairment without other neurological manifestations. In the previous 3 months, the patient had consulted several times to the health care system due to bilateral otitis media, which did not improve with conventional treatments. Daily fever, diarrhea and weight loss were added to the picture. After admission to the Infectious Diseases department, she was diagnosed with advanced HIV infection and disseminated tuberculosis (TB) with pulmonary, intestinal, lymph node and otic involvement. This case underlines the complexity of diagnosing TB otitis media, especially in the context of HIV co-infection, and highlights the importance of routine HIV screening in patients with persistent, unexplained symptoms to facilitate early diagnosis and prevent complications.</div></div>","PeriodicalId":39211,"journal":{"name":"Clinical Microbiology Newsletter","volume":"50 ","pages":"Pages 1-6"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142704208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acute appendicitis caused by Arcanobacterium haemolyticum 溶血隐杆菌引起的急性阑尾炎

Clinical Microbiology Newsletter Pub Date : 2025-03-01 Epub Date: 2025-01-02 DOI: 10.1016/j.clinmicnews.2024.12.001

Ismail Faiz , Abderrazak Saddari , Said Ezrari , Samir Kaddouri , Elmostafa Benaissa , Yassine BenLahlou , Mostafa Elouennass , Adil Maleb

{"title":"Acute appendicitis caused by Arcanobacterium haemolyticum","authors":"Ismail Faiz , Abderrazak Saddari , Said Ezrari , Samir Kaddouri , Elmostafa Benaissa , Yassine BenLahlou , Mostafa Elouennass , Adil Maleb","doi":"10.1016/j.clinmicnews.2024.12.001","DOIUrl":"10.1016/j.clinmicnews.2024.12.001","url":null,"abstract":"<div><div><em>Arcanobacterium haemolyticum</em> is known for causing pharyngitis in young adults and skin/soft tissue infections in older and immunocompromised people. We report here the case of a 25-year-old patient admitted to the emergency room for pain in the right iliac fossa. Abdominal computed tomography (CT) scan showed acute uncomplicated appendicitis. The biological assessment revealed an inflammatory syndrome with CRP at 124 mg/L. The patient underwent an appendectomy by laparotomy. The cytobacteriological analysis of deep pus revealed an important leukocyte reaction to neutrophils, and the growth of <em>Arcanobacterium haemolyticum</em> in culture. Antibiotic susceptibility testing showed that the bacterium was susceptible to clindamycin, tetracycline, linezolid, and rifampicin, and resistant to penicillin G, sulfamethoxazole/trimethoprim, moxifloxacin, ciprofloxacin, and vancomycin. Most studies have shown that this bacterium is susceptible to all classes of antibiotics except sulfamethoxazole-trimethoprim, however, in our case and like certain recent studies, other resistances are emerging.</div></div>","PeriodicalId":39211,"journal":{"name":"Clinical Microbiology Newsletter","volume":"50 ","pages":"Pages 19-23"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143095473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Maximizing the diagnostic potential of 1,3 beta-D-glucan assays for invasive fungal infections 最大化1,3 β - d -葡聚糖检测对侵袭性真菌感染的诊断潜力

Clinical Microbiology Newsletter Pub Date : 2025-03-01 Epub Date: 2025-01-10 DOI: 10.1016/j.clinmicnews.2025.01.001

Sejal Morjaria , N. Esther Babady

引用次数: 0

Phage therapy to treat unresponsive infections: A primer for the clinical microbiology laboratory staff 噬菌体治疗无反应性感染：临床微生物实验室工作人员的入门读物

Clinical Microbiology Newsletter Pub Date : 2025-03-01 Epub Date: 2025-01-15 DOI: 10.1016/j.clinmicnews.2025.01.002

Josephine M. Davey-Young , Dinuri D. Punchihewa , Bernadette Ng , Jenna Wong , Greg J. German

{"title":"Phage therapy to treat unresponsive infections: A primer for the clinical microbiology laboratory staff","authors":"Josephine M. Davey-Young , Dinuri D. Punchihewa , Bernadette Ng , Jenna Wong , Greg J. German","doi":"10.1016/j.clinmicnews.2025.01.002","DOIUrl":"10.1016/j.clinmicnews.2025.01.002","url":null,"abstract":"<div><div>With the increase in antimicrobial resistance and subsequent need for alternatives to traditional antibiotics, phage therapy (PT) has gained a renewed interest. Much like antibiotics, bacteriophages or simply phages, have shown promise in eradicating bacterial infections; however, their fundamental differences require specific laboratory protocols and practices. As bacterial-specific viruses, they must be detected, replicated, and purified for safety and efficacy. The narrow spectrum of activity of phages provides a targeted approach to infection but also necessitates expansive libraries and susceptibility testing to match phages to bacteria. Such testing is not standardized, complicating both research and clinical efforts. This review then provides a background on PT in the clinical microbiology laboratory and an overview of such protocols and practices specific to PT, such as classic susceptibility testing methods and updated approaches. Also covered are the challenges and future directions for the field, as well as resources for clinical and research laboratory personnel.</div></div>","PeriodicalId":39211,"journal":{"name":"Clinical Microbiology Newsletter","volume":"50 ","pages":"Pages 48-59"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143095476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Medically important alphaviruses in the United States and how to test for them 美国医学上重要的字母病毒及其检测方法

Clinical Microbiology Newsletter Pub Date : 2024-12-01 Epub Date: 2024-11-04 DOI: 10.1016/j.clinmicnews.2024.10.003

Allison R. Eberly

{"title":"Medically important alphaviruses in the United States and how to test for them","authors":"Allison R. Eberly","doi":"10.1016/j.clinmicnews.2024.10.003","DOIUrl":"10.1016/j.clinmicnews.2024.10.003","url":null,"abstract":"<div><div>Alphaviruses are arthropod-borne viruses (i.e. arboviruses) transmitted by mosquitos that are classically divided into two groups that infect humans: encephalitic and arthralgia-associated. While the encephalitic alphaviruses are primarily endemic in North and South America, alphaviruses associated with arthralgia are distributed globally. Given the overlapping clinical manifestations of alphaviruses with other arboviruses, diagnosis is dependent on both exposure history and laboratory testing. In the United States, diagnostic approaches largely rely on detection of host antibodies against these viruses via enzyme-linked immunosorbent assays (ELISAs) or indirect immunofluorescence assays (IFAs) in serum and/or cerebrospinal fluid. Positive results can be confirmed by plaque reduction neutralization testing (PRNT), which remains the reference standard method for anti-alphavirus antibody detection. Increasingly, select public health and reference laboratories are also offering molecular testing for certain alphaviruses, including chikungunya virus and Eastern equine encephalitis virus. Molecular testing, however, is most useful in acutely ill, viremic patients who present within the first week of symptom onset. There are no targeted antivirals for treatment, and prevention relies on protection from mosquito bites.</div></div>","PeriodicalId":39211,"journal":{"name":"Clinical Microbiology Newsletter","volume":"49 ","pages":"Pages 28-36"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142701833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

“Eye see worms on the down Loa”: A case study of microfilarial co-infection "眼见虫子下罗亚"：微丝蚴合并感染病例研究

Clinical Microbiology Newsletter Pub Date : 2024-12-01 Epub Date: 2024-10-10 DOI: 10.1016/j.clinmicnews.2024.10.001

Christopher George Kendra , Kevin Andrew Smith , Trina Trusty , Amber Ryan , Kenneth Gavina

引用次数: 0

Current scenario and future prospect of scabies treatment: A comprehensive review 疥疮治疗的现状与前景：全面回顾

Clinical Microbiology Newsletter Pub Date : 2024-12-01 Epub Date: 2024-10-16 DOI: 10.1016/j.clinmicnews.2024.10.002

Nishan Hazra , Soutik Sarkar , Srijita Chakrabarti

引用次数: 0

General perspectives on dengue fever 关于登革热的一般观点

Clinical Microbiology Newsletter Pub Date : 2024-12-01 Epub Date: 2024-09-24 DOI: 10.1016/j.clinmicnews.2024.09.002

Oluwabunmi Bola Olajide , Joshua Seun Olajide , Olusanya Olasehinde

{"title":"General perspectives on dengue fever","authors":"Oluwabunmi Bola Olajide , Joshua Seun Olajide , Olusanya Olasehinde","doi":"10.1016/j.clinmicnews.2024.09.002","DOIUrl":"10.1016/j.clinmicnews.2024.09.002","url":null,"abstract":"<div><div>Dengue is the leading arboviral disease of major public health importance across the globe. Severe dengue causes bleeding and shock, and can be life threatening, terminating in death. There has been considerable success in vector territorial mapping, disease transmission process, diagnosis and molecular characterization of the virus. However, continuous sporadic outbreaks and re-emergence of dengue infections are common in recent time. Also, limited treatment options, weak host immune response in sequential infection, inadequate preventive measures in some areas and continual territorial expansion of the vectors are factors sustaining dengue transmission. In this review, we present an overview of dengue virus, disease predisposing factors, surveillance tools and control measures. In addition, we offer suggestions on future research direction to deepen the control efforts. Nonetheless, continual re-emergence of dengue requires redirection from antibody-dependent enhancement and the use of insecticides into environmentally favourable bio-control and molecular surveillance of the vector until effective vaccines are readily available.</div></div>","PeriodicalId":39211,"journal":{"name":"Clinical Microbiology Newsletter","volume":"49 ","pages":"Pages 1-9"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142426161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Navigating the new norm: The FDA's final rule on laboratory developed tests (LDTs) and its impact on clinical laboratory operations 驾驭新规范：美国食品和药物管理局关于实验室开发测试 (LDT) 的最终规定及其对临床实验室运作的影响

Clinical Microbiology Newsletter Pub Date : 2024-09-01 Epub Date: 2024-09-16 DOI: 10.1016/j.clinmicnews.2024.09.001

Rob E. Carpenter

{"title":"Navigating the new norm: The FDA's final rule on laboratory developed tests (LDTs) and its impact on clinical laboratory operations","authors":"Rob E. Carpenter","doi":"10.1016/j.clinmicnews.2024.09.001","DOIUrl":"10.1016/j.clinmicnews.2024.09.001","url":null,"abstract":"<div><div>On April 29, 2024, the U.S. Food and Drug Administration (FDA) issued a transformative final rule impacting the regulatory landscape for laboratory-developed tests (LDTs). This new regulation categorizes in vitro diagnostics (IVDs) used as LDTs under the same stringent oversight applied to other medical devices, thereby phasing out the agency's long-standing policy of enforcement discretion. This paper offers a concise historical overview and examines the FDA's revised regulatory framework scheduled for the next four years, examining its impact on laboratory operations in terms of safety, efficacy, and innovation. It explores how the new rule's increased compliance demands and economic implications impact laboratory operations, including economic stability, innovation, and patient safety. Also highlighted is how certain laboratories gain strategic advantages that could enhance their market stability and attract investors. The overall intent of this paper is not an in-depth analysis but instead it aims to inform stakeholders in health services about evolving laboratory standards. By doing so, it equips healthcare participants to strategically align with emerging regulatory demands, enhancing comprehension of how these changes influence healthcare delivery and laboratory procedures.</div></div>","PeriodicalId":39211,"journal":{"name":"Clinical Microbiology Newsletter","volume":"48 ","pages":"Pages 1-8"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142357840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0